RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

If the HI data are good, corx might be able to get the foundation to act as a VC to fund the clinical trials that they would otherwise have to go to BP for.

The biggest hurdle with the HI is whether or not the side-effects are acceptable. If there's a dosage level that is clinically effective, but below the seizure-inducing threshold, this could generate a great deal of interest, because of the broad beneficial effects of BDNF in PD and AD.